{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.97","value":"-3.2"},{"groupId":"OG001","spread":"1.03","value":"-4.1"},{"groupId":"OG002","spread":"1.13","value":"-3.1"}]}],"title":"Change from Baseline at Week 4 [N=41; 37; 33]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.03","value":"-4.8"},{"groupId":"OG001","spread":"1.06","value":"-6.4"},{"groupId":"OG002","spread":"1.18","value":"-5.7"}]}],"title":"Change from Baseline at Week 8 [N=39; 36; 31]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.11","value":"-4.7"},{"groupId":"OG001","spread":"1.29","value":"-6.9"},{"groupId":"OG002","spread":"1.47","value":"-5.7"}]}],"title":"Change from Baseline at Week 12 [N=40; 30;26]"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.95","value":"-4.8"},{"groupId":"OG001","spread":"1.03","value":"-6.9"},{"groupId":"OG002","spread":"1.11","value":"-5.0"}]}],"title":"Change from Baseline at EOT [N=47; 40; 36]"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"58"}],"units":"Participants"}],"description":"Quality of life was assessed by the ICIQ-LUTSqol questionnaire which consists of 19 questions each on a 1-4 scale (larger scores correspond to less quality of life). The total symptom score ranges from 19 - 76.\n\nLeast squares means were derived from an ANCOVA model with the pooled study center and treatment as factors and the baseline value as a covariate.","dispersionType":"Standard Error","groups":[{"description":"Participants received matching mirabegron placebo tablets orally once daily for 12 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants received 50 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG001","title":"Mirabegron 50 mg"},{"description":"Participants received 100 mg mirabegron tablets orally once daily for 12 weeks.","id":"OG002","title":"Mirabegron 100 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set included all patients who received at least 1 dose of double-blind study drug \\& had both Qmax \\& PdetQmax measurements at baseline \\& 1 or both at any postbaseline on-treatment visit. End of treatment (EOT) includes the last on-treatment assessment for patients who didn't complete Week 12; N is the number of patients included.","reportingStatus":"POSTED","timeFrame":"Baseline and Weeks 4, 8 and 12","title":"Change From Baseline to Weeks 4, 8, 12 and End of Treatment in International Consultation on Incontinence Questionnaire - Lower Urinary Tract Symptom Quality of Life (ICIQ-LUTSqol) Symptom Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}